Document

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 Form 8-K  

 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (date of earliest event reported): November 7, 2018
 

 
DAVITA INC.
(Exact name of registrant as specified in its charter)
 
 
Delaware
1-14106
No. 51-0354549
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
 
2000 16th Street
Denver, CO 80202
(Address of principal executive offices including Zip Code)
 
(303) 405-2100
(Registrant’s telephone number, including area code)
 
Not applicable
(Former name or former address, if changed since last report)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 240.425)
 
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
☐    Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 





Item 2.02 Results of Operations and Financial Condition.
 
On November 7, 2018, DaVita Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2018. A copy of the press release is furnished as Exhibit 99.1 to this report.
 
The information contained in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
 
Item 9.01. Financial Statements and Exhibits.
 
(d) Exhibits.
 
 
 
Exhibit
Number
Description
Press Release dated November 7, 2018 announcing the registrant’s financial results for the three and nine months ended September 30, 2018.





SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
DAVITA INC.
 
 
 
Date: November 7, 2018
By:
/s/ James K. Hilger
 
 
James K. Hilger
 
 
Chief Accounting Officer






EXHIBIT INDEX
 
 
 
Exhibit Number 
Description 
Press Release dated November 7, 2018 announcing the registrant’s financial results for the three and nine months ended September 30, 2018.




Exhibit


http://api.tenkwizard.com/cgi/image?quest=1&rid=23&ipage=12536169&doc=3


Contact:        Jim Gustafson
Investor Relations                    
DaVita Inc.
(310) 536-2585

DaVita Inc. 3rd Quarter 2018 Results
Denver, Colorado, November 7, 2018 — DaVita Inc. (NYSE: DVA) today announced results for the quarter ended September 30, 2018.
Third quarter 2018 financial results - from continuing operations:
Consolidated revenues of $2,847 million.
Operating income of $289 million, including notable charges totaling $93 million.
Cash flow of $362 million and free cash flow of $226 million.
Net income (loss):
Three months ended September 30,
 
Nine months ended September 30,
 
 
2018
 
2017
 
2018
 
2017
 
 
(dollars in millions, except per share data)
 
Attributable to DaVita Inc.:
 
 
 
 
 
 
 
 
Net income from continuing operations
$
73

 
$
153

 
$
464

 
$
745

 
Per share
$
0.44

 
$
0.80

 
$
2.66

 
$
3.85

 
Adjusted net income from continuing operations(1)
$
93

 
$
162

 
$
467

 
$
465

 
Per share adjusted(1)
$
0.56

 
$
0.85

 
$
2.68

 
$
2.40

 
Net (loss) income
$
(137
)
 
$
(214
)
 
$
309

 
$
360

 
Per share
$
(0.82
)
 
$
(1.12
)
 
$
1.77

 
$
1.86

Operating income:
Three months ended September 30,
 
Nine months ended September 30,
 
 
2018
 
2017
 
2018
 
2017
 
 
(dollars in millions)
 
Operating income
$
289

 
$
395

 
$
1,138

 
$
1,662

 
Adjusted operating income(1)
$
314

 
$
404

 
$
1,143

 
$
1,185


 
(1) 
For the definitions of non-GAAP financial measures such as adjusted net income from continuing operations attributable to DaVita Inc., see the note titled “Note on Non-GAAP Financial Measures” below.
Current items impacting operating income:
Advocacy costs: During the three months ended September 30, 2018, we incurred advocacy costs of $45 million in countering union policy efforts, including ballot initiatives. These costs are included in the U.S. dialysis and related lab services segment in general and administrative expenses.

1



Equity compensation: During the third quarter of 2018, the Company adopted a retirement policy which applies to outstanding equity awards which resulted in additional stock-based compensation expense in the quarter of $23 million related to modification charges and net acceleration of expense. This expense is included in the corporate administrative support segment.
Non-GAAP adjustments to operating income:
Restructuring charges: In connection with our planned transition of our pharmacy business' customer service and fulfillment functions to third parties and the winding down of our distribution operation, we recognized restructuring charges of $11 million in the third quarter of 2018, which are included in general and administrative expense, as well as additional asset impairment charges of $6 million during the third quarter of 2018.
APAC JV goodwill impairment charge: During the third quarter of 2018 we also recognized a reduction in equity earnings of $6 million as a result of goodwill impairment charges recognized by our Asia Pacific joint venture (APAC JV).
 
Three months ended September 30,
 
Nine months ended September 30,
 
2018
 
2017
 
2018
 
2017
 
(dollars in millions)
Impairment charges
$
12

 
$
6

 
$
26

 
$
56

Restructuring charges
11

 
3

 
11

 
3

Gain on settlement, net

 

 

 
(530
)
Loss (gain) on changes in ownership interests, net
2

 

 
(32
)
 
(6
)
Proposition 8: Proposition 8, a California statewide ballot initiative, was proposed by the Service Employees International Union - United Healthcare Workers West and sought to limit the amount of revenue dialysis providers can retain from caring for commercial patients by requiring rebates to insurers and taking into account only a portion of the costs incurred by dialysis providers. Proposition 8 was not approved in the November 2018 election.
Pending sale of DMG: As previously announced in December 2017, we entered into an agreement to sell our DaVita Medical Group (DMG) division to Optum, a subsidiary of UnitedHealth Group Inc. The transaction is subject to receipt of required regulatory approvals and other customary closing conditions. As a result, the DMG business is classified as held for sale and its results of operations are reported as discontinued operations for all periods presented. During the third quarter of 2018, we recorded a $216 million charge on our DMG business which included a $98 million valuation adjustment and $118 million in related tax expense on this held for sale business based on an updated assessment of fair value, which includes inputs such as the transaction itself, risks and timing, and performance of the business.
Financial and operating metrics include:
Cash flow:
Three months ended September 30,
 
Twelve months ended September 30,
 
 
2018
 
2017
 
2018
 
2017
 
 
(dollars in millions)
 
Operating cash flow
$
458

 
$
553

 
$
1,727

 
$
2,050

 
Operating cash flow from continuing operations
$
362

 
$
355

 
$
1,460

 
$
1,701

 
Free cash flow from continuing operations
$
226

 
$
221

 
$
908

 
$
1,182

Volume: Total U.S. dialysis treatments for the third quarter of 2018 were 7,377,277, or 94,580 treatments per day, representing a per day increase of 4.0% over the third quarter of 2017. Normalized non-acquired treatment growth in the third quarter of 2018 as compared to the third quarter of 2017 was 3.3%.
Effective income tax rate: Our effective income tax rate on income from continuing operations was 31.1% and 26.2% for the three and nine months ended September 30, 2018. These effective income tax rates are impacted by the amount of third party owners' income attributable to non-tax paying entities. The effective income tax rate on income from continuing operations attributable to DaVita Inc. was 41.4% and 30.8% for the three and nine months ended September 30, 2018, respectively.
Our effective income tax rate on income from continuing operations for the three and nine months ended September 30, 2018 was impacted by the impairment charges, net loss (gain) on business ownership changes and restructuring charges

2



related to our pharmacy business. Excluding these items from their respective periods, our effective income tax rate on adjusted income from continuing operations attributable to DaVita Inc. for the three and nine months ended September 30, 2018 would have been 38.0% and 30.9%, respectively. Our effective income tax rate on adjusted income from continuing operations attributable to DaVita Inc. was impacted during these periods by the non-deductible advocacy costs and additional non-deductible expenses related to the Tax Cuts and Jobs Act of 2017, partially offset by the return to provision adjustments. 
Center activity: As of September 30, 2018, we provided dialysis services to a total of approximately 226,000 patients at 2,876 outpatient dialysis centers, of which 2,625 centers were located in the United States and 251 centers were located in 10 countries outside of the United States. During the third quarter of 2018, we opened a total of 47 new dialysis centers, acquired three dialysis centers, and closed five centers in the United States. We also closed two dialysis centers outside of the United States.
Share repurchases: During the quarter ended September 30, 2018, we repurchased a total of 4,849,051 shares of our common stock for approximately $344 million at an average price of $70.86 per share. We have not repurchased any shares of our common stock subsequent to September 30, 2018. As of November 5, 2018, we have repurchased a total of 16,844,067 shares of our common stock for approximately $1,154 million at an average price of $68.48 per share during 2018.
On July 11, 2018, our Board of Directors approved an additional share repurchase authorization in the amount of approximately $1,390 million. This authorization was in addition to the approximately $110 million remaining at that time under our Board of Directors' prior share repurchase authorization approved in October 2017. As of November 5, 2018, we have a total of approximately $1,356 million in outstanding Board repurchase authorizations remaining under our stock repurchase program. These share repurchase authorizations have no expiration dates.
Outlook
The following forward-looking measures and the underlying assumptions involve significant risks and uncertainties, including those described below, and actual results may vary significantly from these current forward-looking measures. We do not provide guidance for Kidney Care consolidated operating income or effective income tax rate on income from continuing operations on a GAAP basis nor a reconciliation of the forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures on a forward-looking basis because we are unable to predict certain items contained in the GAAP measures without unreasonable efforts. The following non-GAAP financial measures do not include certain items, including goodwill and other asset impairment charges, restructuring charges, gain (loss) on ownership changes and foreign currency fluctuations.
We now expect our Kidney Care adjusted consolidated operating income for 2018 to be in the range of $1.5 billion to $1.525 billion.
Our previous guidance for our Kidney Care adjusted consolidated operating income for 2018 was in the range of $1.5 billion to $1.6 billion.
We still expect our operating cash flow from continuing operations for 2018 to be in the range of $1.4 billion to $1.6 billion.
We now expect our 2018 effective income tax rate on income from continuing operations attributable to DaVita Inc. to be approximately 30.5% to 31.5%.
Our previous guidance for our 2018 effective income tax rate on income from continuing operations attributable to DaVita Inc. was approximately 28.5% to 29.5%.
We will be holding a conference call to discuss our results for the third quarter ended September 30, 2018 on November 7, 2018 at 5:00 p.m. Eastern Time. To join the conference call, please dial (877) 918-6630 from the U.S. or (517) 308-9042 from outside the U.S., and provide the operator the password 'Earnings'. A replay of the conference call will be available on our website at investors.davita.com for the following 30 days.

3



Note on Non-GAAP Financial Measures
As used in this press release, the term “adjusted” refers to non-GAAP measures as follows, each as reconciled to its most comparable GAAP measure as presented in the non-GAAP reconciliations in the notes to this press release: (i) for income measures, the term “adjusted” refers to operating performance measures that exclude certain items such as impairment charges, (gain) loss on ownership changes, restructuring charges, and gains and charges associated with settlements; and (ii) the term “effective income tax rate on adjusted income from continuing operations attributable to DaVita Inc.” represents the Company’s effective tax rate excluding applicable non-GAAP items and noncontrolling owners’ income, which primarily relates to non-tax paying entities.
These non-GAAP or “adjusted” measures are presented because management believes these measures are useful adjuncts to GAAP results. However, these non-GAAP measures should not be considered alternatives to the corresponding measures determined under GAAP. 
Specifically, we use adjusted operating income, adjusted net income from continuing operations attributable to DaVita Inc. and adjusted diluted net income from continuing operations per share attributable to DaVita Inc. to compare and evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe these non-GAAP measures are useful to management, investors and analysts in evaluating our performance over time and relative to competitors, as well as in analyzing the underlying trends in our business. We also believe these presentations enhance a user's understanding of our normal consolidated operating income by excluding certain items which we do not believe are indicative of our ordinary results of operations. As a result, adjusting for these amounts allows for comparison to our normalized prior period results.
In addition, the effective income tax rate on income from continuing operations attributable to DaVita Inc. excludes noncontrolling owners' income, which primarily relates to non-tax paying entities, and the effective income tax rate on adjusted income from continuing operations attributable to DaVita Inc. excludes noncontrolling owners' income and certain non-deductible and other charges which we do not believe are indicative of our ordinary results. Accordingly, we believe these adjusted effective income tax rates are useful to management, investors and analysts in evaluating our performance and establishing expectations for income taxes incurred on our ordinary results attributable to DaVita Inc.
Finally, free cash flow from continuing operations represents net cash provided by operating activities from continuing operations less distributions to noncontrolling interests and capital expenditures for routine maintenance and information technology from continuing operations. We believe this non-GAAP measure is useful to management, investors and analysts as an adjunct to cash flow from operating activities from continuing operations and other measures under GAAP, since free cash flow from continuing operations is meaningful for assessing our ability to fund acquisition and development activities and meet our debt service obligations.
It is important to bear in mind that these non-GAAP "adjusted" measures are not measures of financial performance or liquidity under GAAP and should not be considered in isolation from, nor as substitutes for, their most comparable GAAP measures.
Reconciliations of the non-GAAP measures presented herein to their most comparable GAAP measures are included at Notes 2, 3, 4 and 5 at the end of this press release.

4



DaVita Inc. and its representatives may from time to time make written and oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”), including statements in this release, filings with the Securities and Exchange Commission (“SEC”), reports to stockholders and in meetings with investors and analysts. All such statements in this release, during the related presentation or other meetings, other than statements of historical fact, are forward-looking statements and as such are intended to be covered by the safe harbor for “forward-looking statements” provided by the PSLRA. Without limiting the foregoing, statements including the words “expect,” “intend,” “will,” “plan,” “anticipate,” “believe,” “we are confident that,” “forecast,” “guidance,” “outlook,” “goals,” and similar expressions are intended to identify forward-looking statements.
The forward-looking statements should be considered in light of these risks and uncertainties. All forward-looking statements in this release are based on information available to us on the date of this presentation. We undertake no obligation to publicly update or revise any of our guidance, the assessment of the underlying assumptions or other forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise.
These forward-looking statements could include but are not limited to statements related to our guidance and expectations for our 2018 Kidney Care adjusted consolidated operating income, our 2018 operating cash flows from continuing operations, our 2018 effective income tax rate on income from continuing operations attributable to DaVita Inc., our expected costs associated with countering union policy efforts, including ballot initiatives, our expectations regarding the pending DMG sale transaction, our expectations related to our stock repurchase program, and uncertainties associated with the other risk factors set forth in our most recent quarterly report on Form 10-Q and the other risks discussed in our subsequent reports filed with the SEC from time to time.
Our actual results could differ materially from any forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, and are qualified in their entirety by reference to the full text of those risk factors in our SEC filings relating to:
the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates, and a reduction in the number of patients under such plans, including as a result of restrictions or prohibitions on the use and/or availability of charitable premium assistance, which may result in the loss of revenues or patients, or our making incorrect assumptions about how our patients will respond to any change in financial assistance from charitable organizations;
the extent to which the ongoing implementation of healthcare exchanges or changes in or new legislation, regulations or guidance, or enforcement thereof, including among other things those regarding the exchanges, results in a reduction in reimbursement rates for our services from and/or the number of patients enrolled in higher-paying commercial plans;
a reduction in government payment rates under the Medicare End Stage Renal Disease program or other government-based programs;
the impact of the Medicare Advantage benchmark structure;
risks arising from potential and proposed federal and/or state legislation, regulation or ballot or other initiatives, including healthcare-related and labor-related legislation, regulation or ballot or other initiatives;
the impact of the changing political environment and related developments on the current health care marketplace and on our business, including with respect to the future of the Affordable Care Act, the exchanges and many other core aspects of the current health care marketplace;
uncertainties related to the impact of federal tax reform legislation;
changes in pharmaceutical practice patterns, reimbursement and payment policies and processes, or pharmaceutical pricing, including with respect to calcimimetics;
legal compliance risks, such as our continued compliance with complex government regulations and the provisions of our current corporate integrity agreement and current or potential investigations by various government entities and related government or private-party proceedings, and restrictions on our business and operations required by our corporate integrity agreement and other current or potential settlement terms and the financial impact thereof and our ability to recover any losses related to such legal matters from third parties;
continued increased competition from dialysis providers and others, and other potential marketplace changes;
our ability to reduce administrative expenses while maintaining targeted levels of service and operating performance, including our ability to achieve anticipated savings from our recent restructurings;

5



our ability to maintain contracts with physician medical directors, changing affiliation models for physicians, and the emergence of new models of care introduced by the government or private sector that may erode our patient base and reimbursement rates, such as accountable care organizations, independent practice associations and integrated delivery systems;
our ability to complete acquisitions, mergers or dispositions that we might announce or be considering, on terms favorable to us or at all, or to integrate and successfully operate any business we may acquire or have acquired, or to successfully expand our operations and services in markets outside the United States, or to businesses outside of dialysis;
noncompliance by us or our business associates with any privacy laws or any security breach by us or a third party involving the misappropriation, loss or other unauthorized use or disclosure of confidential information;
the variability of our cash flows;
the risk that we may not be able to generate sufficient cash in the future to service our indebtedness or to fund our other liquidity needs, and the risk that we may not be able to refinance our indebtedness as it becomes due, on terms favorable to us or at all;
factors that may impact our ability to repurchase stock under our stock repurchase program and the timing of any such stock repurchases, including market conditions, the price of our common stock, our cash flow position, borrowing capacity and leverage ratios, and legal, regulatory and contractual requirements;
the risk that we might invest material amounts of capital and incur significant costs in connection with the growth and development of our international operations, yet we might not be able to operate them profitably anytime soon, if at all;
risks arising from the use of accounting estimates, judgments and interpretations in our financial statements;
impairment of our goodwill, investments or other assets;
the risks and uncertainties associated with the timing, conditions and receipt of regulatory approvals and satisfaction of other closing conditions of the DMG sale transaction and continued disruption in connection with the DMG sale transaction making it more difficult to maintain business and operational relationships;
risks and uncertainties related to our ability to complete the DMG sale transaction on the terms set forth in the equity purchase agreement or at all;
uncertainties related to our liquidity following the close of the DMG sale transaction and our planned subsequent entry into new external financing arrangements, which may be less than we anticipate;
uncertainties related to our use of the proceeds from the DMG sale transaction and other available funds, including external financing and cash flow from operations, which may be used in ways that may not improve our results of operations or enhance the value of our common stock; 
risks related to certain contractual restrictions on the conduct of DMG’s business while the DMG sale transaction is pending and certain post-closing contractual obligations;
the risk that laws regulating the corporate practice of medicine could restrict the manner in which DMG conducts its business;
the risk that the cost of providing services under DMG’s agreements may exceed our compensation;
the risk that any reductions in reimbursement rates, including Medicare Advantage rates, and future regulations may negatively impact DMG’s business, revenue and profitability;
the risk that DMG may not be able to successfully establish a presence in new geographic regions or successfully address competitive threats that could reduce its profitability;
the risk that a disruption in DMG’s healthcare provider networks could have an adverse effect on DMG’s business operations and profitability;
the risk that reductions in the quality ratings of health plans DMG serves or healthcare services that DMG provides could have an adverse effect on DMG’s business; and
the risk that health plans that acquire health maintenance organizations may not be willing to contract with DMG or may be willing to contract only on less favorable terms.

6



DAVITA INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(dollars in thousands, except per share data)
 
Three months ended
September 30,
 
Nine months ended
September 30,
 
2018
 
2017
 
2018
 
2017
Dialysis and related lab patient service revenues
$
2,670,701

 
$
2,561,543

 
$
7,980,178

 
$
7,478,938

Provision for uncollectible accounts
(11,977
)
 
(119,321
)
 
(35,838
)
 
(335,979
)
Net dialysis and related lab patient service revenues
2,658,724

 
2,442,222

 
7,944,340

 
7,142,959

Other revenues
188,606

 
322,849

 
639,387

 
952,762

Total revenues
2,847,330

 
2,765,071

 
8,583,727

 
8,095,721

Operating expenses and charges:
 

 
 

 
 

 
 

Patient care costs and other costs
2,063,770

 
1,951,609

 
6,168,444

 
5,698,318

General and administrative
336,299

 
272,911

 
866,922

 
798,602

Depreciation and amortization
146,000

 
142,634

 
435,878

 
415,544

Equity investment loss (income)
3,824

 
5,308

 
(6,126
)
 
5,456

Provision for uncollectible accounts
800

 
(2,685
)
 
(7,300
)
 
(1,381
)
Investment and other asset impairments
6,093

 

 
17,338

 
15,168

Goodwill impairment charges

 

 
3,106

 
34,696

Loss (gain) on changes in ownership interests, net
1,506

 

 
(32,451
)
 
(6,273
)
Gain on settlement, net

 

 

 
(526,827
)
Total operating expenses and charges
2,558,292

 
2,369,777

 
7,445,811

 
6,433,303

Operating income
289,038

 
395,294

 
1,137,916

 
1,662,418

Debt expense
(125,927
)
 
(109,306
)
 
(359,135
)
 
(321,637
)
Other income, net
4,007

 
3,396

 
10,583

 
12,180

Income from continuing operations before income taxes
167,118

 
289,384

 
789,364

 
1,352,961

Income tax expense
52,047

 
90,546

 
206,652

 
474,126

Net income from continuing operations
115,071

 
198,838

 
582,712

 
878,835

Net loss from discontinued operations, net of tax
(211,739
)
 
(370,872
)
 
(147,829
)
 
(388,959
)
Net (loss) income
(96,668
)
 
(172,034
)
 
434,883

 
489,876

Less: Net income attributable to noncontrolling interests
(40,128
)
 
(42,442
)
 
(125,717
)
 
(129,654
)
Net (loss) income attributable to DaVita Inc.
$
(136,796
)
 
$
(214,476
)
 
$
309,166

 
$
360,222

Earnings per share attributable to DaVita Inc.:
 

 
 

 
 
 
 
Basic net income from continuing operations per share
$
0.44

 
$
0.81

 
$
2.69

 
$
3.91

Basic net (loss) income per share
$
(0.82
)
 
$
(1.14
)
 
$
1.79

 
$
1.89

Diluted net income from continuing operations per share
$
0.44

 
$
0.80

 
$
2.66

 
$
3.85

Diluted net (loss) income per share
$
(0.82
)
 
$
(1.12
)
 
$
1.77

 
$
1.86

Weighted average shares for earnings per share:
 
 
 
 
 

 
 

Basic
166,770,664

 
188,883,922

 
172,403,944

 
190,770,165

Diluted
167,262,358

 
191,408,117

 
174,348,421

 
193,546,245

Amounts attributable to DaVita Inc.:
 
 
 
 
 
 
 
Net income from continuing operations
$
73,371

 
$
152,870

 
$
463,989

 
$
745,067

Net loss from discontinued operations
(210,167
)
 
(367,346
)
 
(154,823
)
 
(384,845
)
Net (loss) income attributable to DaVita Inc.
$
(136,796
)
 
$
(214,476
)
 
$
309,166

 
$
360,222


7



DAVITA INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(unaudited)
(dollars in thousands)
 
 
Three months ended
September 30,
 
Nine months ended
September 30,
 
2018
 
2017
 
2018
 
2017
Net (loss) income
$
(96,668
)
 
$
(172,034
)
 
$
434,883

 
$
489,876

Other comprehensive (loss) income, net of tax:
 

 
 

 
 
 
 
Unrealized gains (losses) on interest rate cap agreements:
 

 
 

 
 
 
 
Unrealized gains (losses) on interest rate cap agreements
37

 
(478
)
 
819

 
(5,479
)
Reclassifications of net realized gains on interest rate cap agreements into net (loss) income
1,606

 
1,265

 
4,680

 
3,793

Unrealized gains on investments:
 
 
 
 
 
 
 
Unrealized gains on investments

 
863

 

 
3,478

Reclassification of net investment realized gains into net (loss) income

 
(9
)
 

 
(221
)
Unrealized (losses) gains on foreign currency translation:
 
 
 

 
 
 
 

Foreign currency translation adjustments
(8,827
)
 
29,143

 
(39,475
)
 
91,546

Other comprehensive (loss) income
(7,184
)
 
30,784

 
(33,976
)
 
93,117

Total comprehensive (loss) income
(103,852
)
 
(141,250
)
 
400,907

 
582,993

Less: Comprehensive income attributable to noncontrolling interests
(40,128
)
 
(42,442
)
 
(125,717
)
 
(129,652
)
Comprehensive (loss) income attributable to DaVita Inc.
$
(143,980
)
 
$
(183,692
)
 
$
275,190

 
$
453,341



8



DAVITA INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(dollars in thousands)
 
Nine months ended
September 30,
 
2018
 
2017
Cash flows from operating activities:
 

 
 

Net income
$
434,883

 
$
489,876

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 

Depreciation and amortization
435,878

 
593,527

Impairment charges
20,444

 
701,523

Stock-based compensation expense
59,605

 
28,478

Deferred income taxes
200,056

 
(132,781
)
Equity investment loss, net
8,611

 
19,071

Gain on sales of business interests, net
(57,547
)
 
(23,402
)
Other non-cash charges, net
164,856

 
41,703

Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:
 
 
 
Accounts receivable
(74,622
)
 
(146,024
)
Inventories
88,355

 
14,272

Other receivables and other current assets
(757
)
 
(43,556
)
Other long-term assets
2,142

 
(13,831
)
Accounts payable
(12,800
)
 
18,595

Accrued compensation and benefits
40,225

 
(60,063
)
Other current liabilities
45,624

 
39,445

Income taxes
21,749

 
22,669

Other long-term liabilities
5,546

 
18,648

Net cash provided by operating activities
1,382,248

 
1,568,150

Cash flows from investing activities:
 
 
 

Additions of property and equipment
(705,659
)
 
(639,829
)
Acquisitions
(113,526
)
 
(726,538
)
Proceeds from asset and business sales
135,268

 
92,529

Purchase of investments available for sale
(5,791
)
 
(9,882
)
Purchase of investments held-to-maturity
(3,728
)
 
(223,482
)
Proceeds from sale of investments available for sale
8,783

 
5,822

Proceeds from investments held-to-maturity
32,628

 
398,765

Purchase of equity investments
(12,874
)
 
(3,014
)
Distributions received on equity investments
3,580

 
80

Net cash used in investing activities
(661,319
)
 
(1,105,549
)


9



DAVITA INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS - continued
(unaudited)
(dollars in thousands)
 
Nine months ended
September 30,
 
2018
 
2017
Cash flows from financing activities:
 
 
 
Borrowings
41,674,279

 
38,160,821

Payments on long-term debt and other financing costs
(40,828,443
)
 
(38,269,284
)
Purchase of treasury stock
(1,161,511
)
 
(321,411
)
Stock award exercises and other share issuances, net
8,803

 
15,781

Distributions to noncontrolling interests
(139,673
)
 
(165,463
)
Contributions from noncontrolling interests
43,179

 
51,156

Proceeds from sales of additional noncontrolling interests
15

 

Purchases of noncontrolling interests
(19,988
)
 
(1,432
)
Net cash used in financing activities
(423,339
)
 
(529,832
)
Effect of exchange rate changes on cash, cash equivalents and restricted cash
(5,790
)
 
5,449

Net increase (decrease) in cash, cash equivalents and restricted cash
291,800

 
(61,782
)
Less: Net increase in cash, cash equivalents and restricted cash from discontinued
operation
s
270,565

 
82,694

Net increase (decrease) in cash, cash equivalents and restricted cash from continuing
operations
21,235

 
(144,476
)
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year
518,920

 
683,463

Cash, cash equivalents and restricted cash of continuing operations at end of the period
$
540,155

 
$
538,987


10



DAVITA INC.
CONSOLIDATED BALANCE SHEETS
(unaudited)
(dollars in thousands, except per share data)
 
September 30,
2018
 
December 31, 2017
ASSETS
 

 
 

Cash and cash equivalents
$
448,215

 
$
508,234

Restricted cash and equivalents
91,940

 
10,686

Short-term investments
4,730

 
32,830

Accounts receivable, net
1,847,086

 
1,714,750

Inventories
91,102

 
181,799

Other receivables
383,783

 
372,919

Income tax receivable
26,002

 
49,440

Prepaid and other current assets
88,857

 
112,058

Current assets held for sale, net
5,947,786

 
5,761,642

Total current assets
8,929,501

 
8,744,358

Property and equipment, net of accumulated depreciation of $3,454,107 and $3,103,662
3,275,636

 
3,149,213

Intangible assets, net of accumulated amortization of $225,862 and $356,774
97,609

 
113,827

Equity method and other investments
240,820

 
245,534

Long-term investments
35,047

 
37,695

Other long-term assets
76,517

 
47,287

Goodwill
6,702,659

 
6,610,279

 
$
19,357,789

 
$
18,948,193

LIABILITIES AND EQUITY
 

 
 

Accounts payable
$
458,927

 
$
509,116

Other liabilities
560,692

 
552,662

Accrued compensation and benefits
631,799

 
616,116

Current portion of long-term debt
1,784,065

 
178,213

Current liabilities held for sale
1,419,621

 
1,185,070

Total current liabilities
4,855,104

 
3,041,177

Long-term debt
8,440,673

 
9,158,018

Other long-term liabilities
452,445

 
365,325

Deferred income taxes
515,893

 
486,247

Total liabilities
14,264,115

 
13,050,767

Commitments and contingencies:
 
 
 
Noncontrolling interests subject to put provisions
1,064,412

 
1,011,360

Equity:
 

 
 

Preferred stock ($0.001 par value, 5,000,000 shares authorized; none issued)
 

 
 

Common stock ($0.001 par value, 450,000,000 shares authorized; 182,828,547 and
182,462,278 shares issued and 165,984,480 and 182,462,278 shares outstanding,
respectively)
183

 
182

Additional paid-in capital
1,055,839

 
1,042,899

Retained earnings
3,951,247

 
3,633,713

Treasury stock (16,844,067 and zero shares, respectively)
(1,153,511
)
 

Accumulated other comprehensive (loss) income
(29,109
)
 
13,235

Total DaVita Inc. shareholders' equity
3,824,649

 
4,690,029

Noncontrolling interests not subject to put provisions
204,613

 
196,037

Total equity
4,029,262

 
4,886,066

 
$
19,357,789

 
$
18,948,193


11



DAVITA INC.
SUPPLEMENTAL FINANCIAL DATA
(unaudited)
(dollars in millions, except for per share and per treatment data)
 
Three months ended
 
Nine months ended
September 30, 2018
 
September 30,
2018
 
June 30,
2018
 
September 30,
2017
(1)
 
1. Consolidated Financial Results:
 
 
 
 
 
 
 
Consolidated revenues(2)
$
2,847

 
$
2,887

 
$
2,765

 
$
8,584

Operating income
$
289

 
$
438

 
$
395

 
$
1,138

Adjusted operating income excluding certain items(3)
$
314

 
$
419

 
$
404

 
$
1,143

Operating income margin
10.2
%
 
15.2
%
 
14.3
%
 
13.3
%
Adjusted operating income margin excluding certain items(3) (7)
11.0
%
 
14.5
%
 
14.6
%
 
13.3
%
Net income from continuing operations attributable to DaVita Inc.
$
73

 
$
200

 
$
153

 
$
464

Adjusted net income from continuing operations attributable to
DaVita Inc. excluding certain items
(3)
$
93

 
$
183

 
$
162

 
$
467

Diluted net income from continuing operations per share attributable to DaVita Inc.
$
0.44

 
$
1.15

 
$
0.80

 
$
2.66

Adjusted diluted net income from continuing operations per
share attributable to DaVita Inc. excluding certain items
(3)
$
0.56

 
$
1.05

 
$
0.85

 
$
2.68

 
 
 
 
 
 
 
 
2. Consolidated Business Metrics:
 
 
 
 
 
 
 
Expenses
 
 
 
 
 
 
 
General and administrative expenses as a percent of
consolidated revenues
(4) 
11.8
%
 
9.1
%
 
9.9
%
 
10.1
%
Effective income tax rate on income from continuing
operations
31.1
%
 
26.2
%
 
31.3
%
 
26.2
%
Effective income tax rate on income from continuing
operations attributable to DaVita Inc.
(3) 
41.4
%
 
29.5
%
 
37.2
%
 
30.8
%
Effective income tax rate on adjusted income from
continuing operations attributable to DaVita Inc.
(3)
38.0
%
 
30.7
%
 
35.9
%
 
30.9
%
 
 
 
 
 
 
 
 
3. Summary of Division Financial Results:
 
 
 
 
 
 
 
Revenues(2)
 
 
 
 
 
 
 
Kidney Care:
 
 
 
 
 
 
 
U.S. dialysis and related lab patient services and other
$
2,577

 
$
2,588

 
$
2,370

 
$
7,703

Other—Ancillary services and strategic initiatives
 
 
 
 
 
 
 
U.S. other
191

 
221

 
323

 
649

International dialysis patient service and other
113

 
107

 
91

 
324

 
304

 
328

 
414

 
972

Eliminations
(34
)
 
(29
)
 
(19
)
 
(92
)
Total consolidated revenues
$
2,847

 
$
2,887

 
$
2,765

 
$
8,584



12



DAVITA INC.
SUPPLEMENTAL FINANCIAL DATA - continued
(unaudited)
(dollars in millions, except for per share and per treatment data)
 
Three months ended
 
Nine months ended
September 30, 2018
 
September 30,
2018
 
June 30,
2018
 
September 30,
2017
(1)
 
3. Summary of Division Financial Results: (continued)
 
 
 
 
 
 
 
Operating income (loss)
 
 
 
 
 
 
 
Kidney Care:
 
 
 
 
 
 
 
U.S. dialysis and related lab services
$
390

 
$
449

 
$
443

 
$
1,273

Other—Ancillary services and strategic initiatives
 
 
 
 
 
 
 
U.S.
(50
)
 
4

 
(19
)
 
(51
)
International
(10
)
 
(1
)
 
(17
)
 
(13
)
 
(60
)
 
3

 
(37
)
 
(64
)
Corporate administrative support
(41
)
 
(14
)
 
(11
)
 
(71
)
Total consolidated operating income
$
289

 
$
438

 
$
395

 
$
1,138

 
 
 
 
 
 
 
 
4. Summary of Reportable Segment Financial Results:
 
 
 
 
 
 
 
U.S. Dialysis and Related Lab Services
 
 
 
 
 
 
 
Revenue:(2)
 
 
 
 
 
 
 
Net dialysis and related lab patient service revenues
$
2,572

 
$
2,583

 
$
2,366

 
$
7,688

Other revenues
5

 
5

 
5

 
15

Total operating revenues
2,577

 
2,588

 
2,370

 
7,703

Operating expenses:
 
 
 
 
 
 
 
Patient care costs
1,819

 
1,810

 
1,607

 
5,408

General and administrative
233

 
196

 
197

 
626

Depreciation and amortization
139

 
138

 
132

 
412

Equity investment income
(4
)
 
(6
)
 
(8
)
 
(15
)
Total operating expenses
2,187

 
2,139

 
1,928

 
6,430

Segment operating income
$
390

 
$
449

 
$
443

 
$
1,273

 
 
 
 
 
 
 
 
5. U.S. Dialysis and Related Lab Services Business Metrics:
 
 
 
 
 
 
 
Volume
 
 
 
 
 
 
 
Treatments
7,377,277

 
7,331,590

 
7,186,280

 
21,882,892

Number of treatment days
78.0

 
78.0

 
79.0

 
233.5

Treatments per day
94,580

 
93,995

 
90,966

 
93,717

Per day year over year increase
4.0
 %
 
4.2
 %
 
4.3
 %
 
4.3
%
Normalized non-acquired treatment growth year over year
3.3
 %
 
3.4
 %
 
3.3
 %
 
 
Operating net revenues(2)
 
 
 
 
 
 
 
Dialysis and related lab services net revenue per treatment
$
348.62

 
$
352.37

 
$
329.19

 
$
351.33

Revenue per treatment changes from previous quarter
(1.1
)%
 
(0.2
)%
 
(0.2
)%
 
 
Revenue per treatment changes from previous year
5.9
 %
 
6.8
 %
 
(2.2
)%
 
6.3
%
Percent of consolidated revenues
89.6
 %
 
89.0
 %
 
85.2
 %
 
89.0
%


13



DAVITA INC.
SUPPLEMENTAL FINANCIAL DATA - continued
(unaudited)
(dollars in millions, except for per share and per treatment data)
 
Three months ended
 
Nine months ended
September 30, 2018
 
September 30,
2018
 
June 30,
2018
 
September 30,
2017
(1)
 
5. U.S. Dialysis and Related Lab Services Business Metrics:
 (continued)
 
 
 
 
 
 
 
Expenses
 
 
 
 
 
 
 
Patient care costs
 
 
 
 
 
 
 
Percent of total segment operating net revenues
70.6
 %
 
69.9
 %
 
67.8
 %
 
70.2
%
Per treatment
$
246.55

 
$
246.90

 
$
223.58

 
$
247.15

Per treatment changes from previous quarter
(0.1
)%
 
(0.5
)%
 
0.8
 %
 
 
Per treatment changes from previous year
10.3
 %
 
11.3
 %
 
(1.6
)%
 
10.2
%
General and administrative expenses
 
 
 
 
 
 
 
Percent of total segment operating net revenues
9.1
 %
 
7.6
 %
 
8.3
 %
 
8.1
%
Per treatment
$
31.64

 
$
26.80

 
$
27.36

 
$
28.59

Per treatment changes from previous quarter
18.1
 %
 
(1.8
)%
 
1.9
 %
 
 
Per treatment changes from previous year
15.6
 %
 
(0.2
)%
 
 %
 
4.8
%
Accounts receivable
 
 
 
 
 
 
 
Net receivables
$
1,643

 
$
1,646

 
$
1,532

 
 
DSO
59

 
59

 
60

 
 
 
 
 
 
 
 
 
 
6. Discontinued Operations
 
 
 
 
 
 
 
Operating results
 
 
 
 
 
 
 
Net revenues(2)
$
1,253

 
$
1,252

 
$
1,178

 
$
3,733

Expenses
1,261

 
1,193

 
1,165

 
3,680

Goodwill impairment charges

 

 
601

 

Valuation adjustment
98

 

 

 
98

(Loss) income from discontinued operations before taxes
(106
)
 
60

 
(587
)
 
(45
)
Income tax expense (benefit)
106

 
(10
)
 
(216
)
 
103

Net (loss) income from discontinued operations, net of tax
$
(212
)
 
$
70

 
$
(371
)
 
$
(148
)
 
 
 
 
 
 
 
 
7. Cash Flow:
 
 
 
 
 
 
 
Operating cash flow
$
458

 
$
562

 
$
553

 
$
1,382

Operating cash flow from continuing operations
$
362

 
$
606

 
$
355

 
$
1,174

Operating cash flow from continuing operations, last twelve
months
$
1,460

 
$
1,454

 
$
1,701

 
 
Free cash flow from continuing operations(3)
$
226

 
$
470

 
$
221

 
$
758

Free cash flow from continuing operations, last twelve
months
(3)
$
908

 
$
902

 
$
1,182

 
 
Capital expenditures from continuing operations:
 
 
 
 
 
 
 
Routine maintenance/IT/other
$
90

 
$
87

 
$
85

 
$
276

Development and relocations
$
130

 
$
132

 
$
131

 
$
364

Acquisition expenditures
$
22

 
$
73

 
$
30

 
$
111

Proceeds from sale of self-developed properties
$
7

 
$
8

 
$
2

 
$
33




14



 
Three months ended
 
Nine months ended
September 30, 2018
 
September 30,
2018
 
June 30,
2018
 
September 30,
2017
(1)
 
8. Debt and Capital Structure:
 
 
 
 
 
 
 
Total debt(5)(6)
$
10,278

 
$
10,002

 
$
9,132

 
 
Net debt, net of cash and cash equivalents(5)(6)
$
9,830

 
$
9,613

 
$
8,603

 
 
Leverage ratio (see calculation on page 16)
4.29x

 
3.99x

 
3.45x

 
 
Overall weighted average effective interest rate during the
quarter
4.93
%
 
4.91
%
 
4.77
%
 
 
Overall weighted average effective interest rate at end of
the quarter
5.03
%
 
4.99
%
 
4.78
%
 
 
Weighted average effective interest rate on the senior
secured credit facilities at end of the quarter
4.80
%
 
4.72
%
 
4.22
%
 
 
Fixed and economically fixed interest rates as a percentage
of total debt
47
%
 
49
%
 
53
%
 
 
Fixed and economically fixed interest rates, including
interest rate cap agreements, as a percentage of total debt
81
%
 
84
%
 
92
%
 
 
Certain columns, rows or percentages may not sum or recalculate due to the use of rounded numbers.
_________________
(1)
As a result of the pending sale of DMG announced in December 2017, the DMG business has been classified as held for sale and its results of operations are presented as discontinued operations for all periods presented.
(2)
On January 1, 2018, the Company adopted FASB Accounting Standards Codification Topic 606 Revenue from Contracts with Customers using the cumulative effect method for those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning on and after January 1, 2018 are presented under Topic 606, while prior period amounts continue to be reported in accordance with our historical accounting under Revenue Recognition (Topic 605).
(3)
These are non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures to their most comparable measure calculated and presented in accordance with GAAP, and for a definition of adjusted amounts, see attached reconciliation schedules.
(4)
Consolidated percentages of revenues are comprised of the dialysis and related lab services business and other ancillary services and strategic initiatives. General and administrative expenses includes certain corporate support and long-term incentive compensation, as well as restructuring charges and advocacy costs for the three and nine months ended September 30, 2018.
(5)
The reported balance sheet amounts at September 30, 2018, June 30, 2018, and September 30, 2017, exclude $53.6 million, $57.9 million and $67.9 million, respectively, of a debt discount associated with our Term Loan B and other deferred financing costs. The reported balance sheet amounts exclude DMG debt which is classified as held for sale liabilities for all periods presented.
(6)
The reported total debt and net debt, net of cash and cash equivalents, excludes DMG cash and debt classified as held for sale assets and liabilities, respectively, for all periods presented.
(7)
Adjusted operating income margin is a calculation of adjusted operating income divided by consolidated revenues.

15



DAVITA INC.
SUPPLEMENTAL FINANCIAL DATA-continued
(unaudited)
(dollars in thousands)
Note 1: Calculation of the Leverage Ratio
Under the senior secured credit facilities (Credit Agreement), the leverage ratio is defined as all funded debt plus the face amount of all letters of credit issued, minus cash and cash equivalents, including short-term investments, divided by “Consolidated EBITDA”. The leverage ratio determines the interest rate margin payable by the Company for its Term Loan A and revolving line of credit under the Credit Agreement by establishing the margin over the base interest rate (LIBOR) that is applicable. The following leverage ratio was calculated using “Consolidated EBITDA” as defined in the Credit Agreement. The calculation below is based on the last twelve months of “Consolidated EBITDA”, pro forma for routine acquisitions that occurred during the period. The Company’s management believes the presentation of “Consolidated EBITDA” is useful to users to enhance their understanding of the Company’s leverage ratio under its Credit Agreement. The leverage ratio calculated by the Company is a non-GAAP measure and should not be considered a substitute for debt to net income attributable to DaVita Inc., net income attributable to DaVita Inc. or total debt as determined in accordance with United States generally accepted accounting principles (GAAP). The Company’s calculation of its leverage ratio might not be calculated in the same manner as, and thus might not be comparable to, similarly titled measures by other companies.
 
Rolling twelve months ended
September 30, 2018
Net income attributable to DaVita Inc.
$
612,562

Income taxes
(7,200
)
Interest expense
430,674

Depreciation and amortization
619,836

Impairment charges
300,510

Noncontrolling interests and equity investment income, net
175,470

Stock-settled stock-based compensation
66,057

Loss (gain) on changes in ownership interest, net
(57,547
)
Other
125,583

“Consolidated EBITDA”
$
2,265,945

 
 
 
September 30, 2018
Total debt, excluding debt discount and other deferred financing costs of $53.6 million
$
10,314,797

Letters of credit issued
37,187

 
10,351,984

Less: Cash and cash equivalents including short-term investments (excluding DMG’s
physician owned entities cash)
(625,427
)
Consolidated net debt
$
9,726,557

Last twelve months “Consolidated EBITDA”
$
2,265,945

Leverage ratio
4.29x

In accordance with the Credit Agreement, the Company’s leverage ratio cannot exceed 4.50 to 1.00 as of September 30, 2018. At that date the Company’s leverage ratio did not exceed 4.50 to 1.00.


16



DAVITA INC.
RECONCILIATIONS FOR NON-GAAP MEASURES
(unaudited)
(dollars in thousands, except for per share data)

The following Notes 2 through 5 provide reconciliations of the non-GAAP financial measures presented in this press release to their most comparable GAAP measures. For more information on the nature, purposes and limitations of these non-GAAP measures, see our “Note on Non-GAAP Financial Measures” on page 4.
Note 2:
Adjusted net income from continuing operations and adjusted diluted net income from continuing operations per share attributable to DaVita Inc.
 
Three months ended
 
Nine months ended
 
September 30,
2018
 
June 30,
2018
 
September 30,
2017
 
September 30,
2018
 
September 30,
2017
Net income from continuing operations attributable
to DaVita Inc.
$
73,371

 
$
199,603

 
$
152,870

 
$
463,989

 
$
745,067

Goodwill impairment charges

 
3,106

 

 
3,106

 
34,696

Equity investment loss related to APAC JV goodwill
impairments
5,995

 

 
6,293

 
5,995

 
6,293

Impairment of other assets
6,093

 
11,245

 

 
17,338

 
15,168

Restructuring charges
11,366

 

 
1,700

 
11,366

 
1,700

Equity investment loss related to restructuring charges

 

 
1,000

 

 
1,000

Gain on settlement, net

 

 

 

 
(526,827
)
Equity investment income related to gain on
settlement

 

 

 

 
(2,677
)
Loss (gain) on changes in ownership interests, net
1,506

 
(33,957
)
 

 
(32,451
)
 
(6,273
)
Noncontrolling interests associated with
adjustments:
 
 
 
 
 
 
 
 
 
Goodwill impairment charges

 

 

 

 
(9,865
)
Gain on settlement, net

 

 

 

 
24,029

Related income tax
(5,190
)
 
2,652

 
(76
)
 
(2,538
)
 
182,236

Adjusted net income from continuing operations
attributable to DaVita Inc.
$
93,141

 
$
182,649

 
$
161,787

 
$
466,805

 
$
464,547

Diluted net income from continuing operations per share
attributable to DaVita Inc.
$
0.44

 
$
1.15

 
$
0.80

 
$
2.66

 
$
3.85

Goodwill impairment charges

 
0.02

 

 
0.02

 
0.18

Equity investment loss related to APAC JV goodwill impairment
0.04

 

 
0.03

 
0.03

 
0.03

Impairment of other assets
0.04

 
0.06

 

 
0.10

 
0.08

Restructuring charges
0.07

 

 
0.01

 
0.07

 
0.01

Equity investment loss related to restructuring charges

 

 
0.01

 

 
0.01

Gain on settlement, net

 

 

 

 
(2.72
)
Equity investment income related to gain on
settlement

 

 

 

 
(0.01
)
Loss (gain) on changes in ownership interests
0.01

 
(0.20
)
 

 
(0.19
)
 
(0.03
)
Noncontrolling interests associated with
adjustments:
 
 
 
 
 
 
 
 
 
Goodwill impairment charges

 

 

 

 
(0.05
)
Gain on settlement, net

 

 

 

 
0.12

Related income tax
(0.03
)
 
0.02

 

 
(0.01
)
 
0.94

Adjusted diluted net income from continuing operations per share attributable to DaVita Inc.
$
0.56

 
$
1.05

 
$
0.85

 
$
2.68

 
$
2.40

Certain columns or rows may not sum or recalculate due to the use of rounded numbers.

17



DAVITA INC.
RECONCILIATIONS FOR NON-GAAP MEASURES - continued
(unaudited)
(dollars in thousands)
Note 3:    Adjusted operating income
 
Three months ended
 
Nine months ended
 
September 30,
2018
 
June 30,
2018
 
September 30,
2017
 
September 30,
2018
 
September 30,
2017
Consolidated:
 
 
 
 
 
 
 
 
 
Operating income
$
289,038

 
$
438,192

 
$
395,294

 
$
1,137,916

 
$
1,662,418

Goodwill impairment charges

 
3,106

 

 
3,106

 
34,696

Equity investment loss related to APAC JV goodwill
impairments
5,995

 

 
6,293

 
5,995

 
6,293

Impairment of other assets
6,093

 
11,245

 

 
17,338

 
15,168

Restructuring charges
11,366

 

 
1,700

 
11,366

 
1,700

Equity investment loss related to restructuring charges

 

 
1,000

 

 
1,000

Gain on settlement, net

 

 

 

 
(526,827
)
Equity investment income related to gain on
settlement

 

 

 

 
(2,677
)
Loss (gain) on changes in ownership interests, net
1,506

 
(33,957
)
 

 
(32,451
)
 
(6,273
)
Adjusted operating income
$
313,998

 
$
418,586

 
$
404,287

 
$
1,143,270

 
$
1,185,498



























18



DAVITA INC.
RECONCILIATIONS FOR NON-GAAP MEASURES - continued
(unaudited)
(dollars in thousands)

 
Three months ended
 
Nine months ended
 
September 30,
2018
 
June 30,
2018
 
September 30,
2017
 
September 30,
2018
 
September 30,
2017
Consolidated:
 
 
 
 
 
 
 
 
 
U.S. dialysis and related lab services:
 
 
 
 
 
 
 
 
 
Segment operating income
$
390,006

 
$
449,443

 
$
442,777

 
$
1,272,828

 
$
1,837,989

Gain on settlement, net

 

 

 

 
(526,827
)
Equity investment income related to gain on
settlement

 

 

 

 
(2,677
)
Adjusted U.S. dialysis and related lab services
operating income
390,006

 
449,443

 
442,777

 
1,272,828

 
1,308,485

Other - Ancillary services and strategic initiatives:
 
 
 
 
 
 
 
 
 
U.S.
 
 
 
 
 
 
 
 
 
Segment operating (loss) income
(50,170
)
 
3,953

 
(19,245
)
 
(51,403
)
 
(107,817
)
Goodwill impairment charges

 

 

 

 
34,696

Impairment of other assets
6,093

 
11,245

 

 
17,338

 
15,168

Restructuring charges
11,366

 

 

 
11,366

 

Loss (gain) on changes in ownership interests
1,506

 
(35,205
)
 

 
(33,699
)
 

Adjusted operating loss
(31,205
)
 
(20,007
)
 
(19,245
)
 
(56,398
)
 
(57,953
)
International
 
 
 
 
 
 
 
 
 
Segment operating loss
(9,963
)
 
(1,138
)
 
(17,273
)
 
(12,904
)
 
(35,166
)
Goodwill impairment charge

 
3,106

 

 
3,106

 

Equity investment loss related to APAC JV
goodwill impairment
5,995

 

 
6,293

 
5,995

 
6,293

Restructuring charges

 

 
1,700

 

 
1,700

Equity investment loss related to
restructuring charges

 

 
1,000

 

 
1,000

Loss (gain) on changes in ownership interests

 
1,248

 

 
1,248

 
(6,273
)
Adjusted operating (loss) income
(3,967
)
 
3,216

 
(8,279
)
 
(2,555
)
 
(32,446
)
Adjusted Other - Ancillary services and strategic
initiatives
operating loss
(35,172
)
 
(16,791
)
 
(27,524
)
 
(58,952
)
 
(90,399
)
Corporate administrative support:
 
 
 
 
 
 
 
 
 
Segment operating loss
(40,836
)
 
(14,066
)
 
(10,965
)
 
(70,605
)
 
(32,587
)
Adjusted operating income
$
313,998

 
$
418,586

 
$
404,287

 
$
1,143,270

 
$
1,185,498

Certain columns or rows may not sum or recalculate due to the use of rounded numbers.

19



DAVITA INC.
RECONCILIATIONS FOR NON-GAAP MEASURES - continued
(unaudited)
(dollars in thousands)
Note 4:    Effective income tax rates and adjusted effective income tax rates
The effective income tax rate on income from continuing operations and on income from continuing operations attributable to DaVita Inc. is computed as follows: